^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Oba01

    i
    Other names: Oba01, zaptuzumab-MMAE
    Company:
    Yantai Obioadc
    Drug class:
    Microtubule inhibitor, DR5-targeted antibody-drug conjugate
    Related drugs:
    1year
    Therapeutic efficacy of a MMAE-based anti-DR5 drug conjugate Oba01 in preclinical models of pancreatic cancer. (PubMed, Cell Death Dis)
    Oba01 combined with gemcitabine showed better antiproliferative activity than either standalone treatment. In cell- and patient-derived xenografts, Oba01 showed excellent tumoricidal activity in mono- or combinational therapy. Thus, Oba01 may provide a novel biotherapeutic approach and a scientific basis for clinical trials in DR5-expressing patients with PC.
    Preclinical • Journal
    |
    TNFRSF10B (TNF Receptor Superfamily Member 10b)
    |
    gemcitabine • Oba01